Brian Custer1,2, Debra Kessler3, Farnaz Vahidnia1, German Leparc4, David E Krysztof5, Beth Shaz3, Hany Kamel6, Simone Glynn7, Roger Y Dodd8, Susan L Stramer5. 1. Blood Systems Research Institute, San Francisco, California. 2. Department of Laboratory Medicine, University of California San Francisco, San Francisco, California. 3. New York Blood Center, New York, New York. 4. OneBlood, Tampa, Florida. 5. Scientific Support Office, American Red Cross, Gaithersburg, Maryland. 6. Blood Systems, Inc., Scottsdale, Arizona. 7. National Heart, Lung and Blood Institute, National Institutes of Health, Rockville, Maryland. 8. Holland Laboratory, American Red Cross, Rockville, Maryland.
Abstract
BACKGROUND: Risk factor surveillance among infected blood donors provides information on the effectiveness of eligibility assessment and is critical for reducing risk of transfusion-transmitted infection. STUDY DESIGN AND METHODS: American Red Cross, Blood Systems, Inc., New York Blood Center, and OneBlood participated in a case-control study from 2010 to 2013. Donors with serologic and nucleic acid testing (NAT) or NAT-only confirmed human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), or serology-confirmed human T-lymphotropic virus (HTLV) infections (cases) and donors with false-positive results (controls) were interviewed for putative behavioral and demographic risks. Frequencies and adjusted odds ratios (AORs) from multivariable logistic regression analyses for each exposure in cases compared to controls are reported. RESULTS: In the study, 196 HIV, 292 HBV, 316 HCV, and 198 HTLV cases, and 1587 controls were interviewed. For HIV, sex with an HIV+ person (AOR, 132; 95% confidence interval [CI], 27-650) and male-male sex (AOR, 62; 95% CI, 27-140) were primary risk factors. For HBV, first-time donor status (AOR, 16; 95% CI, 10-27), sex with an injection drug user (IDU; AOR, 11; 95% CI, 5-28), and black race (AOR, 11; 95% CI, 6-19) were primary. For HCV, IDU (AOR, 42; 95% CI, 13-136), first time (AOR, 18; 95% CI, 10-30), and a family member with hepatitis (AOR, 15; 95% CI, 6-40) were primary. For HTLV, sex with an IDU (AOR, 22; 95% CI, 10-48), 55 years old or more (AOR, 21; 95% CI, 8-52], and first time (AOR, 15; 95% CI, 9-24) were primary. CONCLUSIONS: Despite education efforts and risk screening, individuals with deferrable risks still donate; they may fail to understand or ignore or do not believe they have risk. Recipients have potential transfusion-transmitted infection risk because of nondisclosure by donors.
BACKGROUND: Risk factor surveillance among infected blood donors provides information on the effectiveness of eligibility assessment and is critical for reducing risk of transfusion-transmitted infection. STUDY DESIGN AND METHODS: American Red Cross, Blood Systems, Inc., New York Blood Center, and OneBlood participated in a case-control study from 2010 to 2013. Donors with serologic and nucleic acid testing (NAT) or NAT-only confirmed human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), or serology-confirmed human T-lymphotropic virus (HTLV) infections (cases) and donors with false-positive results (controls) were interviewed for putative behavioral and demographic risks. Frequencies and adjusted odds ratios (AORs) from multivariable logistic regression analyses for each exposure in cases compared to controls are reported. RESULTS: In the study, 196 HIV, 292 HBV, 316 HCV, and 198 HTLV cases, and 1587 controls were interviewed. For HIV, sex with an HIV+ person (AOR, 132; 95% confidence interval [CI], 27-650) and male-male sex (AOR, 62; 95% CI, 27-140) were primary risk factors. For HBV, first-time donor status (AOR, 16; 95% CI, 10-27), sex with an injection drug user (IDU; AOR, 11; 95% CI, 5-28), and black race (AOR, 11; 95% CI, 6-19) were primary. For HCV, IDU (AOR, 42; 95% CI, 13-136), first time (AOR, 18; 95% CI, 10-30), and a family member with hepatitis (AOR, 15; 95% CI, 6-40) were primary. For HTLV, sex with an IDU (AOR, 22; 95% CI, 10-48), 55 years old or more (AOR, 21; 95% CI, 8-52], and first time (AOR, 15; 95% CI, 9-24) were primary. CONCLUSIONS: Despite education efforts and risk screening, individuals with deferrable risks still donate; they may fail to understand or ignore or do not believe they have risk. Recipients have potential transfusion-transmitted infection risk because of nondisclosure by donors.
Authors: Susan L Stramer; Shimian Zou; Edward P Notari; Gregory A Foster; David E Krysztof; Fatemeh Musavi; Roger Y Dodd Journal: Transfusion Date: 2011-08-02 Impact factor: 3.157
Authors: Shimian Zou; Kerri A Dorsey; Edward P Notari; Gregory A Foster; David E Krysztof; Fatemeh Musavi; Roger Y Dodd; Susan L Stramer Journal: Transfusion Date: 2010-03-12 Impact factor: 3.157
Authors: Susan L Stramer; Edward P Notari; Shimian Zou; David E Krysztof; Jaye P Brodsky; Gary E Tegtmeier; Roger Y Dodd Journal: Transfusion Date: 2010-10-07 Impact factor: 3.157
Authors: Susan L Stramer; David E Krysztof; Jaye P Brodsky; Tracy A Fickett; Benjamin Reynolds; Soisaange Phikulsod; Sineeart Oota; Matthew Lin; John Saldanha; Steven H Kleinman Journal: Transfusion Date: 2011-04-19 Impact factor: 3.157
Authors: C de Almeida-Neto; T T Goncalez; R J Birch; S M F de Carvalho; L Capuani; S C Leão; C Miranda; P C Rocha; A B Carneiro-Proietti; B R Johnson; D J Wright; E L Murphy; B Custer Journal: Vox Sang Date: 2013-03-20 Impact factor: 2.144
Authors: Sumathi Ramachandran; Jamel A Groves; Guo-Liang Xia; Paula Saá; Edward P Notari; Jan Drobeniuc; Amanda Poe; Natasha Khudyakov; Sarah F Schillie; Trudy V Murphy; Saleem Kamili; Chong-Gee Teo; Roger Y Dodd; Yury E Khudyakov; Susan L Stramer Journal: Transfusion Date: 2018-11-30 Impact factor: 3.157
Authors: Farnaz Vahidnia; Susan L Stramer; Debra Kessler; Beth Shaz; German Leparc; David E Krysztof; Simone A Glynn; Brian Custer Journal: Qual Life Res Date: 2016-08-17 Impact factor: 4.147
Authors: Brian Custer; Nicolas Sheon; Bob Siedle-Khan; Lance Pollack; Bryan Spencer; Walter Bialkowski; Pam D'Andrea; Marian Sullivan; Simone Glynn; Alan Williams Journal: Transfusion Date: 2015-07-22 Impact factor: 3.157
Authors: Michelle T Vo; Roberta Bruhn; Zhanna Kaidarova; Brian S Custer; Edward L Murphy; Evan M Bloch Journal: Transfusion Date: 2015-10-28 Impact factor: 3.157
Authors: Julia C Cutts; Brendan Quinn; Clive R Seed; George Kotsiou; Ruth Pearson; Nick Scott; David P Wilson; Mary Ellen Harrod; Lisa Maher; Sharon Caris; Alex J Thompson; Michael Farrell; Joanne Pink; Margaret E Hellard Journal: Transfus Med Hemother Date: 2020-07-23 Impact factor: 3.747